Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 4/2012

01-08-2012

Importance of Blood Rheology in the Pathophysiology of Atherothrombosis

Authors: Aimee Q. Cowan, Daniel J. Cho, Robert S. Rosenson

Published in: Cardiovascular Drugs and Therapy | Issue 4/2012

Login to get access

Abstract

Elevated blood viscosity is an integral component of vascular shear stress that contributes to the site specificity of atherogenesis, rapid growth of atherosclerotic lesions, and increases their propensity to rupture. Ex vivo measurements of whole blood viscosity (WBV) is a predictor of cardiovascular events in apparently healthy individuals and studies of cardiovascular disease patients. The association of an elevated WBV and incident cardiovascular events remains significant in multivariate models that adjust for major cardiovascular risk factors. These prospective data suggest that measurement of WBV may be valuable as part of routine cardiovascular profiling, thereby potentially useful data for risk stratification and therapeutic interventions. The recent development of a high throughput blood viscometer, which is capable of rapidly performing blood viscosity measurements across 10,000 shear rates using a single blood sample, enables the assessment of blood flow characteristics in different regions of the circulatory system and opens new opportunities for detecting and monitoring cardiovascular diseases.
Literature
1.
2.
Frangos SG, Gahtan V, Sumpio B. Localization of atherosclerosis: role of hemodynamics. Arch Surg. 1999;134:1142–9.PubMedCrossRef
3.
Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA. 1999;282:2035–42.PubMedCrossRef
4.
Lee AJ, Mowbray PI, Lowe GD, Rumley A, Fowkes FG, Allan PL. Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study. Circulation. 1998;97:1467–73.PubMedCrossRef
5.
Kensey KR. The mechanistic relationships between hemorheological characteristics and cardiovascular disease. Curr Med Res Opin. 2003;19:587–96.PubMedCrossRef
6.
Rosencranz R, Bogen SA. Clinical laboratory measurement of serum, plasma, and blood viscosity. Am J Clin Pathol. 2006;125:S78–86.PubMed
7.
Cokelet GR, Goldsmith HL. Decreased hydrodynamic resistance in the two-phase flow of blood through small vertical tubes at low flow rates. Circ Res. 1991;68:1–17.PubMedCrossRef
8.
9.
Fung YC. Biomechanics: mechanical properties of living tissues. 1st ed. New York: Springer; 1981. p. 101–37.
10.
Gaehtgens P, Pries AR, Ley K. Structural, hemodynamic and rheological characteristics of blood flow in the circulation. In: Chien S, Dormandy J, Ernst E, Matrai A, editors. Clinical hemorheology: applications in cardiovascular and haematological disease, diabetes, surgery, and gynecology. 1st ed. Boston: Martinus Nijhoff; 1987. p. 97–124.
11.
Meiselman HJ. Rheology of shape-transformed human red cells. Biorheology. 1978;15:225–37.PubMed
12.
Goldsmith HL, Cokelet GR, Gaehtgens P. Robin Fåhraeus: evolution of his concepts in cardiovascular physiology. Am J Physiol. 1989;257:H1005–15.PubMed
13.
Wan J, Forsyth AM, Stone HA. Red blood cell dynamics: from cell deformation to ATP release. Integr Biol. 2011;3:972–81.CrossRef
14.
Dintenfass L. Blood microrheology: viscosity factors in blood flow, ischaemia, and thrombosis. An introduction to molecular and clinical haematology. 1st ed. New York: Appleton-Century-Crofts; 1971.
15.
Dinnar U. Cardiovascular fluid mechanics. 1st ed. Boca Raton: CRC Press; 1981.
16.
Seplowitz AH, Chien S, Smith FR. Effects of lipoproteins on plasma viscosity. Atherosclerosis. 1981;38:89–95.PubMedCrossRef
17.
Leonhardt H, Arntz HR, Klemens UH. Studies of plasma viscosity in primary hyperlipoproteinaemia. Atherosclerosis. 1977;28:29–40.PubMedCrossRef
18.
Ditzel J, Kampmann J. Whole-blood viscosity, hematocrit and plasma protein in normal subjects at different ages. Acta Physiol Scand. 1971;81:264–8.PubMedCrossRef
19.
Harkness J. The viscosity of human blood plasma; its measurement in health and disease. Biorheology. 1971;8:171–93.PubMed
20.
Charm SE, Paz H, Kurland GS. Reduced plasma viscosity among joggers compared with non-joggers. Biorheology. 1979;16:185–9.PubMed
21.
Dintenfass L. Rheology of blood in diagnostic and preventive medicine. 1st ed. London: Butterworth; 1976.
22.
Dormandy JA. Medical and engineering problems of blood viscosity. Biomed Eng. 1974;9:284–9.PubMed
23.
Lowe GD. Blood rheology in arterial disease. Clin Sci (Lond). 1986;71:137–46.
24.
Rosenson RS, Lowe GD. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis. 1998;140:271–80.PubMedCrossRef
25.
Sloop GD, Garber DW. The effects of low-density lipoprotein and high-density lipoprotein on blood viscosity correlate with their association with risk of atherosclerosis in humans. Clin Sci (Lond). 1997;92:473–9.
26.
27.
Høieggen A, Fossum E, Moan A, Enger E, Kjeldsen SE. Whole-blood viscosity and the insulin-resistance syndrome. J Hypertens. 1998;16:203–10.PubMedCrossRef
28.
29.
Fowkes FG, Lowe GD, Rumley A, Lennie SE, Smith FB, Donnan PT. The relationship between blood viscosity and blood pressure in a random sample of the population aged 55 to 74 years. Eur Heart J. 1993;14:597–601.PubMedCrossRef
30.
Smith WC, Lowe GD, Lee AJ, Tunstall-Pedoe H. Rheological determinants of blood pressure in a Scottish adult population. J Hypertens. 1992;10:467–72.PubMedCrossRef
31.
Letcher RL, Chien S, Pickering TG, Sealey JE, Laragh JH. Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects. Role of fibrinogen and concentration. Am J Med. 1981;70:1195–202.PubMedCrossRef
32.
Devereux RB, Case DB, Alderman MH, Pickering TG, Chien S, Laragh JH. Possible role of increased blood viscosity in the hemodynamics of systemic hypertension. Am J Cardiol. 2000;85:1265–8.PubMedCrossRef
33.
34.
Zannad F, Voisin P, Brunotte F, Bruntz JF, Stoltz JF, Gilgenkrantz JM. Haemorheological abnormalities in arterial hypertension and their relation to cardiac hypertrophy. J Hypertens. 1988;6:293–7.PubMedCrossRef
35.
Slonim A, Cristal N. Cardiovascular diseases, blood rheology, and dihydropyridine calcium antagonists. J Cardiovasc Pharmacol. 1992;19:S96–8.PubMed
36.
Kearney-Schwartz A, Virion JM, Stoltz JF, Drouin P, Zannad F. Haemorheological disturbances in hypertensive type 2 diabetic patients—influence of antihypertensive therapy. Fundam Clin Pharmacol. 2007;21:387–96.PubMedCrossRef
37.
Kwiterovich Jr PO. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol. 2000;86:5L–10L.PubMedCrossRef
38.
de Simone G, Devereux RB, Chien S, Alderman MH, Atlas SA, Laragh JH. Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in apparently normal adults. Circulation. 1990;81:107–17.PubMedCrossRef
39.
Rosenson RS, McCormick A, Uretz EF. Distribution of blood viscosity values and biochemical correlates in healthy adults. Clin Chem. 1996;42:1189–95.PubMed
40.
Sloop GD, Garber DW. The effects of low-density lipoprotein and high-density lipoprotein on blood viscosity correlate with their association with risk of atherosclerosis in humans. Clin Sci (Lond). 1997;92:473–9.
41.
Koenig W, Sund M, Ernst E, Mraz W, Hombach V, Keil U. Association between rheology and components of lipoproteins in human blood. Results from the MONICA project. Circulation. 1992;85:2197–204.PubMedCrossRef
42.
Stamos TD, Rosenson RS. Low high density lipoprotein levels are associated with an elevated blood viscosity. Atherosclerosis. 1999;146:161–5.PubMedCrossRef
43.
Jaeger BR. Evidence for maximal treatment of atherosclerosis: drastic reduction of cholesterol and fibrinogen restores vascular homeostasis. Ther Apher. 2001;5:207–11.PubMedCrossRef
44.
Carroll S, Cooke CB, Butterly RJ. Plasma viscosity, fibrinogen and the metabolic syndrome: effect of obesity and cardiorespiratory fitness. Blood Coagul Fibrinolysis. 2000;11:71–8.PubMed
45.
Jax TW, Peters AJ, Plehn G, Schoebel FC. Hemostatic risk factors in patients with coronary artery disease and type 2 diabetes—a two year follow-up of 243 patients. Cardiovasc Diabetol. 2009;8:48.PubMedCrossRef
46.
47.
Cho YI, Mooney MP, Cho DJ. Hemorheological disorders in diabetes mellitus. J Diabetes Sci Technol. 2008;2:1130–8.PubMed
48.
Lowe GD, Drummond MM, Forbes CD, Barbenel JC. The effects of age and cigarette-smoking on blood and plasma viscosity in men. Scott Med J. 1980;25:13–7.PubMed
49.
Levenson J, Simon AC, Cambien FA, Beretti C. Cigarette smoking and hypertension. Factors independently associated with blood hyperviscosity and arterial rigidity. Arteriosclerosis. 1987;7:572–7.PubMedCrossRef
50.
Ernst E, Koenig W, Matrai A, Filipiak B, Stieber J. Blood rheology in healthy cigarette smokers. Results from the MONICA project, Augsburg. Arteriosclerosis. 1988;8:385–8.PubMedCrossRef
51.
Ernst E. Haemorheological consequences of chronic cigarette smoking. J Cardiovasc Risk. 1995;2:435–9.PubMedCrossRef
52.
Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men. Atherosclerosis. 2005;181:101–8.PubMedCrossRef
53.
54.
Fowkes FG, Pell JP, Donnan PT, et al. Sex differences in susceptibility to etiologic factors for peripheral atherosclerosis. Importance of plasma fibrinogen and blood viscosity. Arterioscler Thromb. 1994;14:862–8.PubMedCrossRef
55.
Kameneva MV, Watach MJ, Borovetz HS. Gender difference in rheologic properties of blood and risk of cardiovascular diseases. Clin Hemorheol Microcirc. 1999;21:357–63.PubMed
56.
Yarnell JW, Sweetnam PM, Rumley A, Lowe GD. Lifestyle and hemostatic risk factors for ischemic heart disease: the Caerphilly Study. Arterioscler Thromb Vasc Biol. 2000;20:271–9.PubMedCrossRef
57.
Feher G, Koltai K, Kesmarky G, Szapary L, Juricskay I, Toth K. Hemorheological parameters and aging. Clin Hemorheol Microcirc. 2006;35:89–98.PubMed
58.
Carallo C, Irace C, De Franceschi MS, et al. The effect of aging on blood and plasma viscosity. An 11.6 years follow-up study. Clin Hemorheol Microcirc. 2011;47:67–74.PubMed
59.
Kensey KR, Cho YI. Protective adaptation hypothesis as the etiology of atherosclerosis. J Invasive Cardiol. 1992;4:448–58.
60.
Friedman MH, Bargeron CB, Deters OJ, Hutchins GM, Mark FF. Correlation between wall shear and intimal thickness at a coronary artery branch. Atherosclerosis. 1987;68:27–33.PubMedCrossRef
61.
Texon M. The hemodynamic basis of atherosclerosis. Further observations: the bifurcation lesion. Bull N Y Acad Med. 1976;52:187–200.PubMed
62.
Lowe GD, Fowkes FG, Dawes J, Donnan PT, Lennie SE, Housley E. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation. 1993;87:1915–20.PubMedCrossRef
63.
Danesh J, Collins R, Peto R, Lowe GD. Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J. 2000;21:515–20.PubMedCrossRef
64.
Koenig W, Sund M, Filipiak B, Doring A, Lowel H, Ernst E. Plasma viscosity and the risk of coronary heart disease: results from the MONICA-Augsburg Cohort Study, 1984 to 1992. Arterioscler Thromb Vasc Biol. 1998;18:768–72.PubMedCrossRef
65.
Lowe GD, Lee AJ, Rumley A, Price JF, Fowkes FG. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol. 1997;96:168–73.PubMedCrossRef
66.
Wang S, Boss AH, Kensey KR, Rosenson RS. Variations of whole blood viscosity using Rheolog scanning capillary viscometer. Clin Chim Acta. 2003;332:79–82.PubMedCrossRef
67.
Kim S, Cho YI, Hogenauer WN, Kensey KR. A method of isolating surface tension and yield stress effects in a U-shaped scanning capillary-tube viscometer using a Casson model. J Non-Newtonian Fluid Mech. 2002;103:205–19.CrossRef
Metadata
Title
Importance of Blood Rheology in the Pathophysiology of Atherothrombosis
Authors
Aimee Q. Cowan
Daniel J. Cho
Robert S. Rosenson
Publication date
01-08-2012
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 4/2012
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-012-6402-4

Other articles of this Issue 4/2012

Cardiovascular Drugs and Therapy 4/2012 Go to the issue

OriginalPaper

Impact of Statins on the Coagulation Status of Type 2 Diabetes Patients Evaluated by a Novel Thrombin-Generation Assay

OriginalPaper

Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial

OriginalPaper

Statin-Induced Immunomodulation Alters Peripheral Invariant Natural Killer T-cell Prevalence in Hyperlipidemic Patients

EDITORIAL

Statins Counter the Effects of Hyperlipidemia on iNKT Cells

ISCP PRESIDENT'S LETTER

New Challenges Ahead for the Newer Oral Thrombin Inhibitors that Aim at Replacing Warfarin in Clinical Practice—Any Role for Scientific Societies in the Debate?

ReviewPaper

High Molecular Weight Calmodulin-Binding Protein: 20 Years Onwards—A Potential Therapeutic Calpain Inhibitor

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits